Aflibercept injection phase II results for ME patients


The VEGF Trap-Eye is well-tolerated in patients suffering from macula oedema.

The VEGF Trap-Eye is well tolerated in patients suffering from macula oedema, according to results of the GALILEO Study presented at the 2012 World Ophthalmology Congress in Abu Dhabi.

VEGF Trap-Eye, a fully human fusion protein, was injected in the eyes of 104 randomized ME patients (Group 1), with 68 ME patients randomized to the control group (Group 2). Group 1 received 2 mg injections of VEGF Trap-Eye four times a week for 24 weeks. Group 2 received sham injections for 52, and switched to active therapy until week 76. After six months all patients in the VEGF group were given PRN for a further six months.

Overall, VEGF Trap-Eye was well-tolerated and successful in treating patients with ME. Group 1 demonstrated a mean gain of 18 letters, compared to a mean gain of 3.3 letters in group 2.

Of the patients administered treatment in group 1, 60.2% gained at least 15 letters from baseline to week 52. This is compared to 32.4% in the control group. Treated patients gained a mean of 16.9 letters of vision compared to an average gain of 3.8 letters in the control group.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.